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Respiratory failureAbstract Background: The role of noninvasive positive pressure ventilation (NPPV) has been well
established in the treatment of acute hypercapnic respiratory failure due to chronic obstructive pul-
monary disease (COPD), however, its beneﬁts in clinically stable hypercapnic COPD patients still
not well known, so this trial aimed to assess the efﬁcacy of NPPV in patients with stable hypercap-
nic COPD.
Patients and methods: This study included 30 stable hypercapnic COPD patients hospitalized for
long term stay from June 2012 to May 2014. The 30 patients who met the study criteria were ran-
domized into the control group (15 patients: 13 males and 2 females with mean age 66 ± 6.2) main-
tained on standard treatment and the second group (15 patients: 12 males and 3 females with mean
age 65 ± 7.3) received bi-level positive pressure ventilation added to their standard treatment after
giving a written consent. The patients were evaluated and followed up after initiating this therapy.
Results: After 6 months of NPPV, daytime PaCO2 (mmHg) during spontaneous breathing
decreased from 55.2 ± 6.7 to 47.1 ± 3.1 mmHg and daytime PaO2 (mmHg) on room air increased
from 48 ± 6.1 to 55.1 ± 8.3 with improvement of dyspnea scale and quality of life parameters. This
was achieved with mean inspiratory pressures of 19.7 ± 2.41 cm H2O and mean expiratory pres-
sures of 6.8 ± 1.7 cm H2O.
Conclusions: NPPV is well tolerated and can improve blood gas levels, dyspnea and quality of
life parameters in patients with stable hypercapnic COPD.
ª 2015 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Chronic obstructive pulmonary disease (COPD) is currently a
leading cause of death and disability worldwide [1–3]. As the
disease progressively aggravates, a majority of patients will
develop severe COPD with chronic respiratory failure
(CRF), and some have a hypercapnia condition, in which the
Table 1 Characteristics of the studied patients.
Characteristics Control (n= 15) NIPPV (n= 15) P
Age in years 66 ± 6.2 65 ± 7.3 0.68
Gender M/F 13/2 12/3 0.62
BMI (kg/m2) 24.3 ± 4.7 25.1 ± 3.3 0.59
FEV1 (% pred.) 31.1 ± 11.1 30.1 ± 12.2 0.81
PaO2 (mmHg) 48.9 ± 5.8 48.0 ± 6.1 0.67
PaCO2 (mmHg) 54.9 ± 7.3 55.2 ± 6.7 0.9
BMI = body mass index; M=male; F = female.
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persistently >45 mmHg. Once CRF and hypercapnia are pre-
sented, patients often develop severe dyspnea and the quality
of life is worse. Meanwhile, the two-year mortality reaches
30–40% [4,5].
The clinical course of COPD is characterized by a high
morbidity and mortality despite long-term oxygen therapy
(LTOT) [1]. Recent alternative therapies, including lung trans-
plantation and lung volume reduction surgery, can only be
undertaken in a small number of patients, and there is no
demonstration of improved long-term survival rate [2,3].
Noninvasive positive pressure ventilation (NPPV) adminis-
tered via a nasal mask has proven useful in treating restrictive
extra-pulmonary respiratory insufﬁciency and in many
patients with severe COPD in acute respiratory failure [5,6].
Theoretically, NPPV could also be beneﬁcial in patients with
severe stable COPD, through several mechanisms. It could
improve nocturnal ventilation, decrease the end-expiratory
lung volume and hence the level of dynamic hyperinﬂation.
In addition, NPPV could improve respiratory muscle function
by resting the respiratory muscles [7] however; the efﬁcacy of
this form of therapy in patients with airﬂow obstruction who
are in stable condition remains controversial [4]. A previous
meta-analysis showed that nocturnal NIPPV for stable hyper-
capnic patients with COPD did not have clinically or sta-
tistically signiﬁcant effects on lung function, gas exchange, or
sleep efﬁciency [8], but on the other hand, some recent studies
[9,10] using a relative high inspiratory positive airway pressure
(IPAP) in NIPPV showed improvement in gas exchange. So
this trial aimed to assess the efﬁcacy of NPPV compared to
conventional standard treatment in patients with stable hyper-
capnic COPD.
Patients and methods
This study included 30 stable hypercapnic COPD patients
hospitalized for long term stay in the period from June 2012
to May 2014, after giving written informed consent. The study
protocol was approved by the ethics committee of the hospital.
The diagnosis of COPD was based on clinical history, physical
examination ﬁndings, and spirometric criteria according to the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines [1]. All patients were in stable clinical state
and were free from exacerbations at least 4 weeks preceding
recruitment.
An exacerbation of COPD was deﬁned as ‘‘a sustained wor-
sening of the patient’s condition, from the stable state and
beyond normal day-to-day variations, that is acute in onset
and necessitates a change in regular medication’’ [11].
Patients were excluded if they had the following: sleep
apnea syndrome, other etiologies of chronic airway obstruc-
tion (e.g. bronchiectasis) or signiﬁcant co-existing medical con-
ditions, such as left ventricular failure.
The 30 patients who met the study criteria were randomized
into the control group (15 patients, 13 males and 2 females with
mean age 66 ± 6.2) who maintained on standard treatment
(bronchodilators, inhaled corticosteroids, supplemental oxygen
therapy, antibiotics and systemic corticosteroids during the epi-
sodes of acute exacerbation) and the second group (15 patients,
12 males and 3 females with mean age 65 ± 7.3) received in
addition to the previous medications bi-level positive airway
pressure ventilation (BiPAP). The patients were connected toa ventilator (BiPAP Vision, Respironics Inc., Murrysville,
Pa., USA). Initial ventilator settings were: inspiratory positive
airway pressure (IPAP) was set at 10 cm H2O, positive end-
expiratory pressure (EPAP) at 5 cm H2O and then, IPAP and
EPAP were titrated according to the patient’s comfort and syn-
chrony with the ventilator and a marked reduction in the use of
accessory muscles. Arterial blood gases were measured 1 h after
the initiation of ventilation and a decrease in PaCO2 values
>5% was considered as adequate ventilator support, this
was achieved with mean inspiratory pressures of
19.7 ± 2.4 cm H2O and mean expiratory pressures of
6.8 ± 1.7 cm H2O. NPPV is ﬁrst used during daytime under
careful supervision. Once daytime NPPV is tolerated, nocturnal
NPPV is commenced. Finally, patients are instructed to use the
ventilator for the entire night [12].
All patients were evaluated and followed up by:
– Spirometry, performed according to American Thoracic
Guidelines as previously described [13].
– Arterial blood gas analysis.
– A 6-min walk test was performed along a ﬂat indoor hall-
way using standard procedures [14].
– Dyspnea was assessed with the Medical Research Council
(MRC) dyspnea scale [15].
– The evaluation of health related quality of Life (HRQoL)
was made using the 12-Item Short-Form health survey ver-
sion 2 (SF-12V2). The scales can be aggregated to two sum-
mary measures (PCS, physical component summary and
MCS, mental component summary) [16].
Statistical analysis
Results are given as means ± SD. The SPSS package (SPSS,
Chicago) was used for all analyses. P< 0.05 was considered
as statistically signiﬁcant.
Results
Table 1 shows Patients’ baseline characteristics in which there
were no statistically signiﬁcant differences between groups
according to their age, gender, body mass index, spirometric
values and arterial blood gases.
Table 2 shows blood gas parameters (on room air) at the
start and after 6 months of the studied patients. Signiﬁcant
decrease in PaCO2 (mmHg) and signiﬁcant improvement in
PaO2 (mmHg) were observed in patients who received
NPPV, however there were no signiﬁcant changes in the con-
trol group.
Table 3 Lung function parameters (during spontaneous breathing) at the start and after 6 months of the studied patients.
Variables Patients treated with NPPV Control group
Base-line parameters After 6 months P Base-line parameters After 6 months P
FVC (% pred.) 48.3 ± 13.3 49.6 ± 13.7 0.74 47.9 ± 13.3 46.1 ± 12.2 0.69
FEV1 (% pred.) 30.8 ± 10.2 33.4 ± 11.1 0.31 31.4 ± 10.1 30.1 ± 9.6 0.72
FEV1/FVC (%) 45.6 ± 10.1 46.1 ± 10.2 0.89 46.2 ± 9.7 45.9 ± 10.2 0.92
FVC= forced vital capacity; FEV1 = forced expiratory volume in one second.
Table 4 Quality of life of the studied patients.
Variables Patients treated with NPPV Control group
Baseline After 6 months. P Baseline After 6 months P
MRC dyspnea scale 4.2 ± 0.8 3. 1 ± 1.1 0.004 4.1±.6 4±.4 0.59
SF-12 V2
PCS 30 ± 5 42 ± 5 0.00 32 ± 3 33 ± 4 0.44
MCS 30 ± 10 40 ± 80 0.004 31 ± 5 32 ± 6 0.43
6-min walk distance 240 ± 30 270 ± 40 0.02 233 ± 31 235 ± 34 0.83
MRC=medical research council; SF-12 V2 = short-form health survey version 2; PCS = physical component summary; MCS =mental
component summary.
Table 5 Exacerbation number and mortality during the study
period.
Variables Patients treated
with NPPV
Control
group
P
No. of exacerbation 1.7 ± 1.6 1.9 ± 1.4 0.73
Mortality number 1 1 1
Table 2 Blood gas parameters (on room air) at the start and after 6 months of the studied patients.
Variables Patients treated with NPPV Control group
Base-line parameters After 6 months P Base-line parameter After 6 months P
pH 7.38 ± 0.02 7.38 ± 0.05 0.99 7.37 ± 0.04 7.37 ± 0.04 1
PaCO2 (mmHg) 55.2 ± 6.7 47.1 ± 3.1 0.008 54.9 ± 7.3 53.3 ± 6.6 0.52
PaO2 (mmHg) 48.0 ± 6.1 55.1 ± 8.3 0.009 48.9 ± 5.8 50.0 ± 7.1 0.6
HCO3
 (mmol/L) 31.3 ± 5.7 26.9 ± 4.2 0.019 30.6 ± 5.6 31.4 ± 4.9 0.6
PaCO2 = arterial partial pressure of carbon dioxide; PaO2 = arterial partial pressure of oxygen; HCO3
= bicarbonate.
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neous breathing) at the start and after 6 months of the studied
patients in which no signiﬁcant changes were observed in both
groups.
Table 4 shows quality of life of the studied patients: there
were signiﬁcant improvement of dyspnea, physical and mental
components of the SF-12 and 6-min walk distance in patients
who received NIPV, however there were no signiﬁcant changes
in these parameters the control group.
Table 5 shows no difference in the number of exacerbation
and mortality in the studied patients during the study period.
One patient died in each group due to COPD exacerbations.
Discussion
Noninvasive positive pressure ventilation (NPPV) adminis-
tered via a nasal mask has proven useful in treating restrictive
extra-pulmonary respiratory insufﬁciency and in many
patients with severe COPD in acute respiratory failure [5,6].
Theoretically, NPPV could also be beneﬁcial in patients with
severe stable COPD, through several mechanisms. It could
improve nocturnal ventilation, decrease the end-expiratory
lung volume and hence the level of dynamic hyperinﬂation
and improve the response of the respiratory center to CO2.It could also decrease upper airway resistance and improve
the quality of sleep. In addition, NPPV could improve respira-
tory muscle function by resting the respiratory muscles [7],
However, the role of noninvasive positive pressure ventilation
(NIPPV) in COPD, especially in severe stable COPD, remains
controversial [4].
A previous meta-analysis showed that nocturnal NIPPV for
stable hypercapnic patients with COPD did not have clinically
or statistically signiﬁcant effects on lung function, gas
exchange, or sleep efﬁciency [8], but on the other hand, some
recent studies [9,10] using a relative high IPAP in NIPPV
showed improvement in gas exchange. Possible factor that
may explain the difference between the results of these studies
was the level of ventilatory pressure utilized and its conse-
quences on effective ventilation.
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PaCO2 and a signiﬁcant improvement in PaO2 in the studied
COPD patients who received NPPV, this agree with the study
of Meecham Jones et al. [12] which showed signiﬁcant
improvements in daytime arterial PaO2 and PaCO2, total sleep
time, sleep efﬁciency, overnight PaCO2, and quality of life of
stable hypercapnic COPD patients with NIV.
In this study there was signiﬁcant improvement in 6-min
walk distance after 6 months in COPD patients treated with
NIV. Similar to this ﬁndings, Garrod et al. [16] demonstrated
a signiﬁcant improvement in the mean shuttle walk test after
8 weeks of NIV therapy.
At present, few treatments could substantially improve lung
function in patients with severe stable COPD, therefore, a
treatment should be considered effective if it could maintain
the lung function or slow down its deterioration. Recently,
Dreher et al. [10] reported that high intensity (HI) NIPPV
could signiﬁcantly improve FEV1 and VC in a prospective ran-
domized crossover study. The present study did not show sig-
niﬁcant change in FEV1%, FVC% and FEV1/FVC in the
COPD patients who received NIPPV.
As most chronic diseases could not be completely cured,
many patients concerned about the quality of life much more
than anything else, therefore, any treatment which could
improve the quality of life should be considered effective, espe-
cially for those end stage COPD patients. In this study there
was improvement in the health related quality of life assessed
by SF-12 V2 and dyspnea evaluated by MRC dyspnea scale
this goes with the results of some previous studies which
reported signiﬁcant improvements in several aspects of health
related quality of life of stable hypercapnic COPD on NIPPV
when comparing with the control group [17,18].
During the study period there was no difference in exacer-
bation number or mortality between the control group or the
group which received NIPPV as one patient died in each group
due to COPD exacerbation this ﬁndings are comparable with
study of Vasiliki et al. [19].
The compliance of the patients using NIPPV was pretty
good in the studied patients this agrees with Dreher et al.
[10] who reported that treatment compliance of HI-NIPPV
was even better than low intensity (LI) NIPPV.
In conclusionNPPV is well tolerated and can improve blood
gas levels, dyspnea and Quality of Life in patients with stable
hypercapnic COPD.
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